Hangzhou Alltest Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 27, 2022 at 07:07 am EDT
Share
Hangzhou Alltest Biotech Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 2,098.92 million compared to CNY 288.24 million a year ago. Revenue was CNY 2,098.92 million compared to CNY 288.24 million a year ago. Net income was CNY 1,049.21 million compared to CNY 150.28 million a year ago. Basic earnings per share from continuing operations was CNY 16.39 compared to CNY 3.72 a year ago.
Hangzhou Alltest Biotech Co Ltd is a China-based company mainly engaged in the development and production of in vitro diagnostic reagents. The Companyâs main products are rapid diagnostic reagents, including drug and drug abuse testing, infectious disease testing, womenâs health testing, tumor testing, and heart marker testing. The Company's products are widely used in clinical testing, on-site testing and personal health management, especially in some new drug testing, new coronavirus testing, tropical infectious disease testing, respiratory all-in-one inspection, pediatric diarrhea all-in-one inspection and all-in-one joint inspection of fecal occult blood and other fields. The Company's main business is mainly distributed in overseas regions.